Want to get me riled up?
There’s a new false hope being marketed to you.
Vitamins & a Flat Earth: My spring Spin editorial
Can one be critical of unproven stem cell therapies but not unproven alternative therapies?
Snotty spine: a good investment?
In the latest The Spin editorial, Chris McBride discusses balancing SCI research for better outcomes.
New research restores voluntary movement after complete SCI
“If it was just about the walking, spinal cord injury would be easy.” This statement by an SCI BC Peer Coordinator is consistent with what the majority of people with SCI have been telling researchers for years – that walking is not the most important return of function to them.
Does a surge in StemCells Inc stock price mean a cure for SCI is closer?
On February 12, StemCells Inc released their twelve-month results from the first patient cohort in the company’s Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury. Investors liked what they heard, sending StemCells Inc’s stock price soaring. Could this mean a cure for SCI is around the corner?